Verenium Corp

Verenium — Diversa — Jefferies 3rd Global Clean Technology Conference 2007

31 slides from Verenium's conference presentation, May 3, 2007

  1. Slide 1: Jefferies 3rd Global Clean Technology Conference May 2, 2007

    Jefferies 3 rd Global Clean Technology Conference May 2, 2007

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This discussion will include forward-looking statements that involve a high degree of risk and uncertainty. These include statements related to Celunol and/or Diversa's products, product candidates and business strategies, including for biofuels, the markets for Celunol an

  3. Slide 3: Accelerating the Production of Cellulosic Biofuels: Company and Merger Overview

    Accelerating the Production of Cellulosic Biofuels + Company and Merger Overview

  4. Slide 4: Key Highlights: First fully-integrated cellulosic ethanol technology company

    Key Highlights First fully-integrated cellulosic ethanol technology company • Superior operating platform – First company with end-to-end cellulosic ethanol capabilities • Deep, diversified product portfolio – Expertise in enzyme development combined with large-scale enzyme production • Blue-chip in

  5. Slide 5: Diversa: Leader in High-performance Specialty Enzymes

    Diversa: Leader in High-performance Specialty Enzymes Pioneer in the discovery and development of high-performance specialty enzymes Who is Diversa? Products/ Markets Achievements Strategy Leader in discovery & commercialization of proprietary enzymes Own world’s broadest array of enzymes Specialty

  6. Slide 6: Diversa: Key Technologies

    Diversa: Key Technologies 250+ issued patents and 500+ pending patents • Biodiversity – Unique access and patented approaches to capture nature’s enormous array of microbial biodiversity • DirectEvolution ™ Technologies – Multiple methods to optimize enzyme performance via laboratory evolution at th

  7. Slide 7: Diversa: Focused Biofuels Strategy

    Diversa: Focused Biofuels Strategy Celunol transaction complements series of preceding initiatives Jan 2006 Feb 2006 Mar 2006 Oct 2006 Dec 2006 Feb 2007 2 3 4 7 8 Diversa and Celunol announce intention to merge Jan 2007 Jan 2007 Focus on biofuels as part of strategic reorganization FDA approval of F

  8. Slide 8: Keys to Success for a Cellulosic Ethanol Company

    Keys to Success for a Cellulosic Ethanol Company • Critical First-Mover Advantages – Foundational process optimization and commercial expertise – Leading partner for complementary state-of-the-art technologies – Worldwide BD partner of choice – Magnet for world-class scientific and operational talen

  9. Slide 9: Celunol: Leader in Emerging Cellulosic Ethanol Sector

    Celunol: Leader in Emerging Cellulosic Ethanol Sector Leading technology, production and development capabilities Overview Asset Base Human Capital + IP Achievements • Founded in 1994 in Massachusetts • Exclusive rights to breakthrough cellulosic ethanol technology • First pilot plant in the US firs

  10. Slide 10: Celunol: Proven Technologies

    BW34 Cellulose (C6 Sugars) KO11 Hemicellulose (C5 Sugars) Exclusive worldwide rights to 2 uniquely designed micro-organisms Celunol: Proven Technologies BW34 Cellulose (C6 Sugars) Goal: High-yield, multi-feedstock, low-cost cellulosic ethanol production KO11 Hemicellulose (C5 Sugars) The Celunol Pro

  11. Slide 11: Merger Rationale

    Merger Rationale Diversa expertise Celunol expertise Diversa’s extensive enzyme capabilities + Celunol’s process and development expertise • Gene discovery • Enzyme development • Enzyme production • Operating assets • Proprietary processes • Project development • Opportunity to control the critical

  12. Slide 12: Merger Terms

    Merger Terms We are targeting a June 2007 closing Diversa shareholders to own 76%, Celunol shareholders 24% Pro Forma Ownership: Diversa to issue 15 mm shares of Diversa stock Consideration: Timeline: Diversa to provide $20mm in debt funding for Celunol’s development efforts prior to closing Additio

  13. Slide 13: Strategy and Competitive Advantages

    Strategy and Competitive Advantages

  14. Slide 14: Our Strategy: Five-point Foundation for Success

    Our Strategy: Five-point Foundation for Success • First mover into cellulosic ethanol: – First mover into low-cost, multi-feedstock, commercial-scale cellulosic ethanol • Owner / operator of biofuels: – Develop, own and operate biofuels plants near low-cost feedstocks and refineries • Partnering / l

  15. Slide 15: Combined Company Revenue Sources

    Combined Company Revenue Sources Cellulosic Ethanol Sales Strategic Partnerships Biofuel Technology Licenses Specialty Enzyme Sales Multiple value opportunities across both businesses ENABLING TECHNOLOGY Enzyme Technology Licenses + • Enzyme Discovery & Optimization • Cellulosic Enzyme Cocktails • C

  16. Slide 16: Biofuels Growth Strategy

    Biofuels Growth Strategy Combined company expects 1st commercial-scale cellulosic ethanol facility in 2009 Pilot- Scale Demo-Scale 1.4 MGY First-Generation Commercial-Scale 25-30 MGY (bagasse) First-Generation Commercial-Scale 25-30 MGY (multiple feedstocks) Next-Generation Commercial-Scale 25-50+ M

  17. Slide 17: First-Generation Prototypical Metrics

    First-Generation Prototypical Metrics Preliminary estimates of key parameters for the 1 st commercial facility Likely sugarcane bagasse or other indigenous grasses to SE Feedstock: Southeastern US; most likely Louisiana or Florida Location: 25 to 30 MGY rated capacity Scale: Our Current Estimates fo

  18. Slide 18: Superior Operating Platform

    Superior Operating Platform Existing Diversa + Celunol platforms are highly complementary Co-products Multi-feedstock capable enzyme discovery + production 3 rd party technology licensing Corn Stover Wood Chips Bagasse Switchgrass ethanol

  19. Slide 19: How Do We Compare to the Competition?

    R&D Infrastructure How Do We Compare to the Competition? Cellulosic Ethanol Demo Plant Cellulosic Ethanol Pilot Plant Blue-chip Partnerships Vertically Integrated Value Chain Unmatched combination of technology and operating expertise Flexible Multi- Feedstock Process Iogen Abengoa Broin Mascoma Not

  20. Slide 20: Deep, Diversified Product Portfolio

    Deep, Diversified Product Portfolio Many of Diversa’s products have already been successfully commercialized Markets Marketed Marketed In Development In Development Marketed Marketed Amylase - T Bayovac® - SRS Biofuels Industrial Processes Animal Health/ Nutrition Market Size Status >$150mm (U.S.) >

  21. Slide 21: Future of Existing Enzyme Business

    Future of Existing Enzyme Business Diversa will leverage its existing enzyme leadership to generate profitable revenues • Commercially augment and accelerate cellulosic ethanol production • Grow and sustain a profitable specialty enzyme business • Deploy enzyme technologies across diverse markets •

  22. Slide 22: Blue-chip Industrial Partnerships

    Blue-chip Industrial Partnerships Diversa has had a long history of partnerships with industry leaders Announced delivery (2005) of enzyme cocktail exceeding DOE performance targets Received $500,000 in milestone payments Enzyme cocktail for cellulosic ethanol (corn stover) Agreement to commercializ

  23. Slide 23: Operating Track Record

    Operating Track Record Management teams have delivered on their financial and strategic plans $3.0 $5.4 $9.8 $15.9 $0 $16 2003A 2004A 2005A 2006A Specialty enzyme product revenue growth ($MM)

  24. Slide 24: Operating Track Record: Enzymes for Cellulosic Ethanol

    Operating Track Record Diversa has considerable experience developing enzymes for cellulosic ethanol Cellulosic Enzymes from Termite Guts Integrated Corn Biorefinery New Zealand Biofuels Bagasse Conversion • Thousand of species sampled • Hundreds of new cellulases sequenced & patented • JGI working

  25. Slide 25: Operating Track Record: Facility Status & Timing

    DEMONSTRATION Facility Status & Timing Scientific Foundation Feedstocks Cost Structure Process Optimization Incremental Diversa Contribution LAB PILOT Scaleable, cost-efficient cellulosic ethanol production Operating Track Record Since 1994 Leading scientists in enzymes / cellulosic Multiple: Bagass

  26. Slide 26: Market-Facing Business Areas

    Market-Facing Business Areas Industry-leading pool of experience SPECIALTY ENZYMES BIOFUELS RESEARCH & DEVELOPMENT Enabling Platform

  27. Slide 27: Financial Review

    Financial Review

  28. Slide 28: Our Financial Strategy

    Our Financial Strategy Near-term (12 Months) Long-Term Additional Non-Equity Sources of Capital ¨ Completed $120 million convertible debt financing ¨ 3/31/07 cash balance: $126 million (excluding $20 million shoe) ¨ Federal governmental loan guarantees ¨ State governmental grants ¨ Royalties, milest

  29. Slide 29: Project Financing Strategy

    Project Financing Strategy $81 $81 $22 $39 Non-recourse debt financing to finance a majority of total construction costs $22 $5 $0 $20 $40 $60 $80 $100 $120 $140 First-Gen Next-Gen Company Equity Partner Equity Contribution Non-recourse Debt 35% Equity Cost ~$125 MM Each ($5/gal @ 25 MGY) 65% Non- R

  30. Slide 30: Key Investment Considerations

    Key Investment Considerations First fully-integrated cellulosic ethanol technology company • Superior operating platform – First company with end-to-end cellulosic ethanol capabilities • Deep, diversified product portfolio – Expertise in enzyme development combined with large-scale enzyme production

  31. Slide 31: Jefferies 3rd Global Clean Technology Conference May 2, 2007

    Jefferies 3 rd Global Clean Technology Conference May 2, 2007

Diversa — Jefferies 3rd Global Clean Technology Conference 2007 on 6ix